NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (ROTH), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, announced today that Elemer Piros, Ph.D. has joined the firm as Senior Research Analyst covering the Biotechnology sector.
Prior to joining ROTH, Dr. Piros was the interim CEO of eMMUNITY, Inc, an immunotherapy startup company. Prior to the position at eMMUNITY, Dr. Piros was a publishing senior biotechnology analyst at Rodman & Renshaw and Burrill Securities, covering 80 companies developing products for CNS disorders, inflammation and the diagnosis and treatment of cancer. Previously, Dr. Piros was a buyside biotechnology analyst at Spear, Leeds & Kellogg, a wholly owned subsidiary of Goldman Sachs. From 1990 to 2000, Dr. Piros conducted academic research in the field of neuroscience, focusing on understanding the molecular mechanism of communication in the nervous system. Dr. Piros was ranked as the #1 Biotechnology analysts by the Wall Street Journal in 2006 and by the Financial Times in 2010, both based on stock portfolio performance.
Piros commented, “I am delighted to join ROTH, a highly regarded investment bank with a strong track record in healthcare. I am very impressed by the quality and depth of the ROTH research universe. My goal is to provide a significant contribution by analyzing companies with cutting-edge medical research and translating science and clinical findings to actionable investment recommendations.”
“We are pleased to add Elemer to our award-winning healthcare research team. His experience within the Biotechnology sector and his respected reputation among companies and investors will be valuable assets to our platform,” said Jeff Martin, CFA, ROTH’s Director of Research.
Byron Roth, CEO of ROTH Capital commented, “Elemer is a recognized senior research analyst and brings to ROTH a wealth of industry expertise and relationships that will add important resources to our platform. We are excited to welcome him as a part of the ROTH healthcare team.”
Since the beginning of 2010, ROTH has assisted its Healthcare clients in raising approximately $8.7 billion in over 235 healthcare transactions. ROTH’s Healthcare clients cover a broad spectrum of sectors including biotechnology, pharmaceuticals, medical technologies and devices, and healthcare services. (ROTH as of 02/17/2015)
About Roth Capital Partners, LLC:
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.
